z-logo
open-access-imgOpen Access
Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects
Author(s) -
Astruc B,
Jenkins H,
Jenkins R
Publication year - 2017
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12452
Subject(s) - medicine , qt interval , moxifloxacin , placebo , adverse effect , confidence interval , crossover study , clinical endpoint , randomized controlled trial , anesthesia , pharmacology , antibiotics , alternative medicine , pathology , microbiology and biotechnology , biology
This phase I, randomized, 4‐period, 4‐sequence, double‐blind, active‐ and placebo‐controlled, crossover study assessed the effects of vonoprazan on the QT/QTc interval in healthy subjects. Subjects received single oral doses of vonoprazan 40 mg, vonoprazan 120 mg, moxifloxacin 400 mg (positive control/open label), and placebo. The primary end point was time‐matched, placebo‐corrected, baseline‐adjusted mean Fridericia‐corrected QT interval (ddQTcF). Of 64 subjects (mean age, 37.8 years; 50% male), 63 received all four regimens. One subject discontinued due to nondrug‐related adverse event of tonsillitis. Assay sensitivity was established; lower bound of the one‐sided 95% confidence interval (CI) for ddQTcF was >5 ms between 1.5 and 12 h following moxifloxacin administration. For both doses of vonoprazan, the one‐sided upper 95% CI ddQTcF did not exceed 10 ms. There was no correlation between plasma vonoprazan concentrations and increases in ddQTcF. Vonoprazan was well tolerated. No severe adverse events/deaths were reported. (European Clinical Trials Database Registry: 2011‐004003‐20.)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here